- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07765563
Reliability of Expired Allergens in Patch Testing: A Comparative Study With Non-Expired Series
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
In brief, review of the medical literature showed two comparable studies out of India and Spain suggesting that expired allergen series may be used beyond their labeled expiry dates, with some variability noted amongst duration of expiry, that the investigators will also aim to analyze.
Regarding allergen stability, there were also several studies focused on this domain. The European Society of Contact Dermatitis (ESCD) released guidelines in 2015, outlining optimal methods for allergen storage such as storage at 4 degrees celsius and strict protection from ultraviolet light exposure. While most allergens are dispersed in petrolatum (white soft paraffin), some substances are better tested in solutions such as water (aqueous) or ethanol. Several allergens with high vapour pressure require more frequent renewal and strict storage conditions such as fragrance chemicals, acrylates and isocyanates. Other substances such as glutaraldehyde in petrolatum (pet.) and formaldehyde in aqueous solution (aq.) are susceptible to instability and deterioration. An additional study assessed volatility over time of several select compounds and described high volatility in acrylates, glutaraldehyde, and fragrances, while describing partial volatility of formaldehyde and low volatility of nickel sulfate.
Study participants will include all eligible adults seen in patch testing clinic who maintain an indication for patch testing and consent to participation. The study will be utilizing 10 allergens from the North American Contact Dermatitis Group (NACDG) 80 Series for inclusion in the study.
The allergen selections are primarily based on compounds with a higher likelihood for volatility, in addition to inclusion of two comparator compounds with lower volatility. Expiration intervals include 1 year, 2 years, 3 years, and 4 years. The compounds selected are as follows, including their dispersion compound: nickel sulfate hexahydrate (5% pet.), cobalt (II) chloride hexahydrate (2.5% pet.), hydroperoxides of linalool (1% pet.), hydroperoxides of limonene (0.3% pet.), fragrance mix 1 (8.0% pet.), myroxylon pereirae resin (balsam of Peru) (25.0% pet.), methylchloroisothiazolinone/methylisothiazolinone (MCI/MI) (0.02% aq.), formaldehyde (2.0% aq.), tixocortol-21-pivalate (1.0% pet.), and budesonide (0.1% pet.).
The patch testing results will be compared to corresponding non-expired allergens from the same manufacturer with the same preparation tested simultaneously. Both series will be placed simultaneously in differing locations on the participant's back, ensuring both are placed in sun protected areas with no underlying dermatitis.
Once in clinic, standard patch test series are applied on patch testing day, with the participant instructed not to shower or scratch the area throughout testing. At 48h, the patches are removed and photos are taken of the participant's back which are sent to the Dermatologist for virtual reading. At either 96h or 120h, the participant returns to the clinic for final reading. Both morphology and intensity of positives are graded on a standard patch test scale (irritant reaction), +/- for doubtful, + for erythema and infiltration, ++ for edematous or vesicular and +++ for spreading, bullous or ulcerative. Positive allergens scored + or greater are considered a true allergic contact allergen and assessed for relevance based on clinical context. The Dermatologist provides information sheets on all positive allergens, counsels on the relevance to their clinical history and allergen avoidance going forward, as well as providing the participant with a safe product list via the ACDS Contact Allergen Management Program (CAMP) database.
The investigators are aiming for enrolment of 100 participants which should theoretically provide the study with at least 5-10 participants testing positive to each of the four listed allergens with higher volatility and 20+ participants testing positive to the allergens with lower volatility. The investigators are aiming to assess concordance between expired and non-expired allergen reactions (positive vs negative), in addition to agreement in reaction intensity, differences in morphology, rates of false positives/negatives compared to control and concordance of irritant reaction between interventions.
The study will serve to lend valuable evidence as to whether expired allergens maintain clinical utility and could serve to reduce product waste, lower the economic burden and further improve accessibility of patch testing for use in resource limited settings.
Type d'étude
Inscription (Estimé)
Phase
- Phase 4
Contacts et emplacements
Coordonnées de l'étude
- Nom: Dylan Hollman, Medical Doctor
- Numéro de téléphone: 1-403-955-8444
- E-mail: dylan.hollman@ucalgary.ca
Lieux d'étude
-
-
Alberta
-
Calgary, Alberta, Canada, T2T 5C7
- Richmond Road Diagnostic Treatment Centre
-
Contact:
- Dylan Hollman, Medical Doctor
- Numéro de téléphone: 1-403-955-8444
- E-mail: dylan.hollman@ucalgary.ca
-
Chercheur principal:
- Laurie Parsons, Medical Doctor
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
La description
Inclusion Criteria:
- Adults (age 18 years or older) referred for patch testing.
Exclusion Criteria:
- Relative or absolute contraindication to patch testing
- Wide spread dermatitis prior to patch placement
- Inability to return to clinic for reading of results
- Patient non-consenting
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Diagnostique
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Autre: Enrolled Study Participants
All enrolled participants will be simultaneously patch tested with both expired and non-expired patches.
Therefore, there is no difference in intervention amongst study participants.
|
All enrolled participants will be simultaneously patch tested with both expired and non-expired patches.
Therefore, there is no difference in intervention amongst study participants.
All enrolled participants will be simultaneously patch tested with both expired and non-expired patches.
Therefore, there is no difference in intervention amongst study participants.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Patch Testing Response (Positive/Negative) Concordance Rate (%) Between Non-Expired and Expired Allergens
Délai: Standard patch test series are applied on Day 0. Participant removal of patches on Day 2 and self photos taken and sent to Dermatologist for virtual reading. Final reading completed in clinic by Dermatologist on Day 4 or 5, recording reaction scores.
|
Each allergen will be graded on response using a standard patch test scale including: irritant reaction ['IR'], '+/-' for doubtful, '+' for erythema and infiltration, '++' for edematous or vesicular and '+++' for spreading, bullous or ulcerative response that will be graded by the participating Dermatologist.
Reactions graded '+', "++", or "+++" are consider a positive result.
Concordance rate will be expressed as a percentage (%) between tested allergens that were non-expired and that were expired (i.e.
Nickel sulfate hexahydrate was found to have a 92% concordance rate, meaning that in 92% of cases, the Nickel allergen in the non-expired and expired patches were both found to both be either positive or negative while in 8% of cases the response differed per the scale listed above.)
|
Standard patch test series are applied on Day 0. Participant removal of patches on Day 2 and self photos taken and sent to Dermatologist for virtual reading. Final reading completed in clinic by Dermatologist on Day 4 or 5, recording reaction scores.
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Reaction/Morphology Scoring Concordance (%)
Délai: Standard patch test series are applied on Day 0. Participant remove patches on Day 2, photos taken and sent to Dermatologist for virtual reading. Final reading completed in clinic by Dermatologist on Day 4 or 5, recording reaction scores, morphology.
|
For each positive allergen, severity (i.e.
'+/-', '+', '++', "+++") and morphology (i.e.
erythema, infiltration, edematous, vesicular, bullous, ulcerated) will be recorded.
Concordance rate will be expressed as a percentage (%) between tested allergens that were non-expired and that were expired (i.e.
Nickel sulfate hexahydrate was found to have a 92% concordance rate, meaning that in 70% of cases, the Nickel allergen in the non-expired and expired patches were both found to have the exact same severity and morphology, while in 30% of cases the severity and/or morphology differed per the scale listed above.)
|
Standard patch test series are applied on Day 0. Participant remove patches on Day 2, photos taken and sent to Dermatologist for virtual reading. Final reading completed in clinic by Dermatologist on Day 4 or 5, recording reaction scores, morphology.
|
|
Stability Concordance (%) Amongst Mediums
Délai: Standard patch test series are applied on Day 0. Participant remove patches on Day 2, photos taken and sent to Dermatologist for virtual reading. Final reading completed in clinic by Dermatologist on Day 4 or 5, recording reaction scores, morphology.
|
Each allergen is suspended within a medium, either petrolatum or aqueous solution.
Not only will concordance (%) of positive and negative reactions be assessed amongst allergens and compared between non-expired and expired, but also between mediums to determine if there is a difference in stability over time amongst mediums used to determine if particular mediums result in degradation over time.
|
Standard patch test series are applied on Day 0. Participant remove patches on Day 2, photos taken and sent to Dermatologist for virtual reading. Final reading completed in clinic by Dermatologist on Day 4 or 5, recording reaction scores, morphology.
|
|
Irritant Reaction Rates (%)
Délai: Standard patch test series are applied on Day 0. Participant remove patches on Day 2, photos taken and sent to Dermatologist for virtual reading. Final reading completed in clinic by Dermatologist on Day 4 or 5, recording reaction scores, morphology.
|
Final patch reading will score reactions on a standarized scale, with irritant reaction representing a negative reaction.
However, we will compare rates and concordance (%) of irritant reactions between allergens to determine if their is reproducibility, or if expired allergens result in differing rates of irritant reactions.
(i.e.
Nickel sulfate allergen was shown to have a 50% increased rate of irritant reactions between the expired to non-expired allergens, meaning that Nickel resulted in an irritant reaction in 6 cases of the expired Nickel and 4 cases of the non-expired Nickel, suggesting that expired Nickel allergens may become more irritating over time, resulting in more irritant reactions.
|
Standard patch test series are applied on Day 0. Participant remove patches on Day 2, photos taken and sent to Dermatologist for virtual reading. Final reading completed in clinic by Dermatologist on Day 4 or 5, recording reaction scores, morphology.
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Laurie Parsons, Medical Doctor, University Of Calgary
Publications et liens utiles
Publications générales
- Houle MC, DeKoven JG, Atwater AR, Reeder MJ, Warshaw EM, Pratt MD, Belsito DV, Adler BL, Silverberg J, Yu J, Botto N, Mowad CM, Dunnick CA, Taylor JS. North American Contact Dermatitis Group Patch Test Results: 2021-2022. Dermatitis. 2025 Sep-Oct;36(5):464-476. doi: 10.1089/derm.2024.0474. Epub 2025 Apr 24.
- Schalock PC, Dunnick CA, Nedorost S, Brod B, Warshaw E, Mowad C, Scheman A; American Contact Dermatitis Society Core Allergen Series Committee. American Contact Dermatitis Society Core Allergen Series: 2020 Update. Dermatitis. 2020 Sep-Oct;31(5):279-282. doi: 10.1097/DER.0000000000000621.
- Siegel PD, Fowler JF, Law BF, Warshaw EM, Taylor JS. Concentrations and stability of methyl methacrylate, glutaraldehyde, formaldehyde and nickel sulfate in commercial patch test allergen preparations. Contact Dermatitis. 2014 May;70(5):309-15. doi: 10.1111/cod.12169.
- Mowitz M, Svedman C, Zimerson E, Bruze M. Fragrance patch tests prepared in advance may give false-negative reactions. Contact Dermatitis. 2014 Nov;71(5):289-94. doi: 10.1111/cod.12300. Epub 2014 Sep 18.
- Mose KF, Andersen KE, Christensen LP. Stability of selected volatile contact allergens in different patch test chambers under different storage conditions. Contact Dermatitis. 2012 Apr;66(4):172-9. doi: 10.1111/j.1600-0536.2011.02035.x.
- Goon AT, Bruze M, Zimerson E, Sorensen O, Goh CL, Koh DS, Isaksson M. Variation in allergen content over time of acrylates/methacrylates in patch test preparations. Br J Dermatol. 2011 Jan;164(1):116-24. doi: 10.1111/j.1365-2133.2010.10087.x.
- Johansen JD, Aalto-Korte K, Agner T, Andersen KE, Bircher A, Bruze M, Cannavo A, Gimenez-Arnau A, Goncalo M, Goossens A, John SM, Liden C, Lindberg M, Mahler V, Matura M, Rustemeyer T, Serup J, Spiewak R, Thyssen JP, Vigan M, White IR, Wilkinson M, Uter W. European Society of Contact Dermatitis guideline for diagnostic patch testing - recommendations on best practice. Contact Dermatitis. 2015 Oct;73(4):195-221. doi: 10.1111/cod.12432. Epub 2015 Jul 14.
- Rodrigues Barata AR, Haroun-Diaz E, Conde-Salazar Gomez L. Can expired TRUE Test(R) be used for patch testing? Contact Dermatitis. 2014 Jun;70(6):381-2. doi: 10.1111/cod.12175. No abstract available.
- Mahajan VK, Chauhan PS, Mehta KS, Sharma A, Chowdhary B, Dhattarwal N, Sharma H, Chandel M, Verma YR. Patch testing with expired Indian patch test kits: Results of a pilot study. Indian J Dermatol Venereol Leprol. 2022 Mar-Apr;88(2):188-195. doi: 10.25259/IJDVL_390_19.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Maladies du système immunitaire
- Hypersensibilité
- Maladies de la peau
- Maladies de la peau, eczémateux
- Hypersensibilité, retardée
- Dermatite
- Maladies de la peau et du tissu conjonctif
- Dermatite de contact
- Dermatite, contact allergique
- Phénomènes physiologiques circulatoires et respiratoires
- Mécanique respiratoire
- Respiration
- Phénomènes physiologiques respiratoires
- Exhalation
Autres numéros d'identification d'étude
- REB26-0539
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .